Inventor · disambiguated record
Paul Averback
Also filed as: AVERBACK PAUL · AVERBACK PAUL A
43 granted patents·17 pending applications·1,146 citations·filing 1987–2024
98Inventor score
Files withNYMOX CORP31NYMOX PHARMACEUTICAL CORP11AVERBACK PAUL9DMS PHARMACEUTICAL INC3NYMOX PHARNACEUTICAL CORP1
Top patents by PatentIndex Score
60 records- 0198US8293703B2Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cellsAVERBACK PAUL·Filed 2008·Granted Oct 23, 2012·110 cites·8 claims
- 0297US7408021B2Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cellsNYMOX PHARMACEUTICAL CORP·Filed 2004·Granted Aug 5, 2008·119 cites·2 claims
- 0397US7317077B2Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cellsNYMOX PHARMACEUTICAL CORP·Filed 2002·Granted Jan 8, 2008·115 cites·2 claims
- 0496US5231170AAntibodies to dense microspheresAVERBACK PAUL·Filed 1990·Granted Jul 27, 1993·153 cites·2 claims
- 0595US6942858B1Compositions containing bacteriophages and methods of using bacteriophages to treat infectionsNYMOX CORP·Filed 2000·Granted Sep 13, 2005·50 cites·12 claims
- 0694US9243035B2Peptides effective in the treatment of conditions requiring the removal or destruction of cellsNYMOX CORP·Filed 2013·Granted Jan 26, 2016·21 cites·13 claims
- 0794US7745572B2Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cellsQUALCOMM INC·Filed 2009·Granted Jun 29, 2010·19 cites·2 claims
- 0893US6461608B1Bacteriophage composition useful in treating food products to prevent bacterial contaminationNYMOX PHARMACEUTICAL CORP·Filed 2000·Granted Oct 8, 2002·40 cites·33 claims
- 0993US5567720APharmaceutically active agents that impede amyloid formation in vivoDMS PHARMACEUTICAL INC·Filed 1994·Granted Oct 22, 1996·91 cites·7 claims
- 1092US8716247B2Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cellsAVERBACK PAUL·Filed 2011·Granted May 6, 2014·17 cites·6 claims
- 1192US8569446B2Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cellsNYMOX CORP·Filed 2012·Granted Oct 29, 2013·14 cites·6 claims
- 1291US6121036ACompositions containing bacteriophages and methods of using bacteriophages to treat infectionsFiled 1997·Granted Sep 19, 2000·94 cites·15 claims
- 1390US8067378B2Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cellsAVERBACK PAUL·Filed 2007·Granted Nov 29, 2011·16 cites·4 claims
- 1489US7241738B2Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cellsNYMOX PHARMACEUTICAL CORP·Filed 2002·Granted Jul 10, 2007·33 cites·8 claims
- 1588US6924266B2NTP-peptides and method for removal of tumorsNYMOX CORP·Filed 2002·Granted Aug 2, 2005·29 cites·7 claims
- 1687US7514407B2Spheron component peptides and pharmaceutical compositionsNYMOX CORP·Filed 2003·Granted Apr 7, 2009·27 cites·12 claims
- 1787US7270818B2Pharmaceutically active agents that impede the formation of amyloid by impeding the genesis or growth of DMSNYMOX CORP·Filed 2002·Granted Sep 18, 2007·21 cites·1 claims
- 1887US7192929B2Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cellsNYMOX CORP·Filed 2002·Granted Mar 20, 2007·22 cites·5 claims
- 1982US10183058B2Method of preventing or reducing the progression of prostate cancerNYMOX CORP·Filed 2016·Granted Jan 22, 2019·2 cites·14 claims
- 2081US6600947B2Method of detecting amyloid-containing lesions by autofluorescenceNYMOX CORP·Filed 2001·Granted Jul 29, 2003·30 cites·47 claims
- 2180US2025049882A1Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating lutsNYMOX CORP·Filed 2024·Application pending·0 cites
- 2275US12090191B2Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTSNYMOX CORP·Filed 2021·Granted Sep 17, 2024·0 cites·14 claims
- 2374US6309892B1Antibodies to components of dense microspheres and methods of using the sameNYMOX PHARMACEUTICAL CORP·Filed 1996·Granted Oct 30, 2001·30 cites·7 claims
- 2473US12329802B2Focal treatment of prostate cancerNYMOX CORP·Filed 2022·Granted Jun 17, 2025·0 cites·11 claims
- 2572US4919915AMethod for detecting the ability to prevent red-to-green congophilic birefringenceAVERBACK PAUL·Filed 1989·Granted Apr 24, 1990·17 cites·13 claims
- 2670US5955285AMethod of identifying individuals at risk of suffering from cerebral amyloidosisNYMOX PHARMACEUTICAL CORP·Filed 1996·Granted Sep 21, 1999·30 cites·4 claims
- 2768US2005191711A1Isolated components of dense microspheres derived from mammalian brain tissue and antibodies theretoNYMOX PHARMACEUTICAL CORP·Filed 2004·Application pending·0 cites
- 2867US4816416AMicrospheric bodies for use in screening therapies for Azheimer's disease and related conditionsAVERBACK PAUL·Filed 1987·Granted Mar 28, 1989·24 cites·7 claims
- 2966US11298400B2Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTSNYMOX CORP·Filed 2019·Granted Apr 12, 2022·0 cites·19 claims
- 3064US2024252516A1Combination bph therapy with fexapotide triflutate, a 5-ari, and an alpha blockerNYMOX CORP·Filed 2023·Application pending·0 cites
- 3163US11231421B2Methods of treating multifocal cancerNYMOX CORP·Filed 2019·Granted Jan 25, 2022·0 cites·11 claims
- 3260US11331374B2Focal treatment of prostate cancerNYMOX CORP·Filed 2019·Granted May 17, 2022·0 cites·9 claims
- 3360US10335453B2Compositions and methods for improving sexual functionNYMOX CORP·Filed 2017·Granted Jul 2, 2019·0 cites·14 claims
- 3458US6518314B1Pharmaceutical agents that impede the initiation and progression of primary and secondary DMS disruptionsNYMOX CORP·Filed 2000·Granted Feb 11, 2003·1 cites·9 claims
- 3557US2007237780A1Method of preventing or reducing the risk or incidence of cancerAVERBACK PAUL·Filed 2007·Application pending·0 cites
- 3656US5525339AIsolated components of dense microspheres derived from mammalian brain tissue and antibodies theretoDMS PHARMACEUTICAL INC·Filed 1993·Granted Jun 11, 1996·6 cites·11 claims
- 3756US2008063598A1Humanized AntibodyNYMOX PHARMACEUTICAL CORP·Filed 2007·Application pending·0 cites
- 3854US11278588B2Method of treating lower urinary tract symptoms with fexapotide triflutateNYMOX CORP·Filed 2019·Granted Mar 22, 2022·0 cites·16 claims
- 3954US2005260171A1Compositions containing bacteriophages and method of using bacteriophages to treat infectionsNYMOX CORP·Filed 2005·Application pending·0 cites
- 4053US6727278B1Pharmaceutically active agents that impede amyloid formation in vivoDMS PHARMACEUTICAL INC·Filed 1995·Granted Apr 27, 2004·8 cites·7 claims
- 4153US2020360466A1Method of improving lower urinary tract symptomsNYMOX CORP·Filed 2019·Application pending·0 cites
- 4251US10835538B2Method of treating benign prostatic hyperlasia with antibioticsNYMOX CORP·Filed 2018·Granted Nov 17, 2020·0 cites·15 claims
- 4351US7544771B2Protein and its use in diagnosing Alzheimer's diseaseNYMOX CORP·Filed 2005·Granted Jun 9, 2009·0 cites·7 claims
- 4451US6130221APharmaceutical agents that impede the initiation and progression of primary and secondary DMS disruptionsNYMOX CORP·Filed 1997·Granted Oct 10, 2000·4 cites·9 claims
- 4549US7572450B2Composition for preventing cell death and/or tissue necrosis resulting from contact with neural thread proteinsNYMOX CORP·Filed 2002·Granted Aug 11, 2009·0 cites·2 claims
- 4649US2005226883A1Humanized antibodyAVERBACK PAUL·Filed 2005·Application pending·0 cites
- 4749US2002028473A1Components of dense microspheres derived from mammalian brain tissue detectable in cerebrospinal fluidFiled 2001·Application pending·0 cites
- 4847US2004002460A1Spheron components useful in determining compounds capable of treating symptoms of Alzheimer's disease, and treatments and animal models produced therefromFiled 2003·Application pending·0 cites
- 4946US11628202B2Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasiaNYMOX CORP·Filed 2015·Granted Apr 18, 2023·0 cites·6 claims
- 5046US10172910B2Method of preventing or reducing the incidence of acute urinary retentionNYMOX CORP·Filed 2016·Granted Jan 8, 2019·0 cites·11 claims
Showing the top 50 of 60 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →